

Genetics 101: cytogenetics and FISH

Alison Sinclair

β See related article page 367

Karyotyping is the isolation, staining and visual examination of chromosomes to find chromosomal rearrangements. Karyotyping is used in prenatal diagnosis (particularly amniocentesis for trisomy 21), investigation of repeat pregnancy loss, investigation of children and adults with features suggestive of a syndrome (dysmorphic features or other associated anomalies, mental retardation, learning disabilities or behavioural anomalies), and subtyping of lymphomas, leukemias and solid tumours^{1,2} for the purpose of exact diagnosis, treatment stratification and prognosis.

Cells are cultured from samples of blood, bone marrow, amniotic fluid, tissue or tumour under sterile conditions for 4–7 days, depending upon the cell type. For karyotyping the chromosomes must be isolated from cells in the metaphase, which is the stage of the cell cycle in which the chromosomes assume their characteristic condensed, discrete shape. Various chemical agents may be added to the cultured cells to synchronize their cell cycles and make it possible to bring the maximum number to a predictable metaphase. The cells are then swollen by the addition of hypotonic solution to disperse the chromosomes, which are fixed chemically, examined microscopically and then stained. Standard G-banding (Giemsa, Leishman's or variant) produces a banding pattern that is characteristic of the individual chromosomes and allows identification of abnormalities in the number and morphology (deletion, addition, translocation of large segments of DNA) of chromosomes (Fig. 1).

Cytogenetic analysis by G-banding cannot resolve structural abnormalities that are small (best resolution is about 2000–3000 kilobases),³ within G-negative bands or involve translocations between regions that have similar staining patterns. Resolution is also dependent upon the cell of origin. Resolution from blood lymphocytes is better than that from fibroblasts grown from amniotic fluid, and both are generally better than cells from tumours.

Resolution of very small deletions (microdeletions) and small translocations is possible with fluorescence in situ hy-





Fig. 1: Standard G-banded karyotype: each chromosome has a characteristic banding pattern, allowing the identification of gross duplications, deletions, additions and translocations.

bridization (FISH).⁴ This technique uses short sequences of single-stranded DNA (probes) that carry fluorescent tags to detect chromosomal DNA with a complementary sequence. Gene-specific probes, also known as “locus specific,” bind to single areas of a chromosome, whether a gene, or a repetitive sequence such as a centromere or telomere. Such locus-specific probes can detect abnormal duplication of a gene (Fig. 2) or chromosome. The use of 2 different gene-specific probes can detect translocations too small to detect by normal karyotyping, such as when genetic material from the *c-abl* oncogene on chromosome 9 is inserted into the *BCR* gene on chromosome 22 as occurs in chronic myelogenous leukemia. Whole chromosome probes are mixtures of smaller, chromosome-specific probes, which allow each chromosome to be “painted” a different colour.^{5,6} Chromosome painting does not detect translocations within chromosomes or allow precise identification of breakpoints. Various extensions of the technique are under development such as spectral banding, which creates a multicoloured banding pattern.⁷



Doug J. Demetrick

Fig. 2: Visualization of genes using locus-specific FISH probes: red signals (see arrows) hybridized to the chromosomes of a metaphase cell and an adjacent interphase nucleus demonstrate normal numbers of the cyclin D1 gene. Inset: excess copies of the *RB1* gene (green) and cyclin D1 gene (red) are demonstrated in human breast cancer cells.

The potential of FISH to detect much smaller chromosomal abnormalities than can be detected with karyotyping has already been mentioned. FISH does not require cells to be in the metaphase before analysis, because it relies upon the presence or absence of a fluorescent signal to identify chromosomes or parts of chromosomes, rather than a specific banding pattern. It allows the surveillance of more

cells and requires a much smaller sample than karyotyping — even down to a single cell. Increasingly, this technique has moved from the research laboratory into routine use, particularly when specimens are in limited quantity (such as those for prenatal diagnosis) or give poor-quality results (tumours) or negative results (microdeletion syndromes) on karyotyping.

Dr. Sinclair is a medical writer in Victoria, BC. She was formerly an Editorial Fellow with *CMAJ*.

Competing interests: None declared.

References

1. Pedersen-Pjergaard J. Molecular cytogenetics in cancer. *Lancet* 2001;357:492-3.
2. Olopade O, Sobulo O, Rowley JD. Recurring chromosomal arrangements in human cancer. In: Bast RC Jr, Gansler TS, Holland JF, Frei E, editors. *Cancer medicine e.5*. Hamilton (ON): BC Decker; 2000.
3. McNeil N, Ried T. Novel molecular cytogenetic techniques for identifying complex chromosomal rearrangements: technology and applications in molecular medicine. *Exp Rev Mol Med* 2000;Sept 14. Available: www.ermm.cbuc.cam.ac.uk/00001940.htm (accessed 2002 July 19).
4. Demetrick DJ. Gone FISHin' for genes. *CMAJ* 1999;161(9):1138.
5. Uhrig S, Schuffenhauer S, Fauth C, Wirtz A, Daumer-Haas C, Apacik C, et al. Multiplex-FISH for pre- and postnatal diagnostic applications. *Am J Hum Genet* 1999;65(2):448-62.
6. Bayani J, Squire JA. Advances in the detection of chromosomal aberrations using spectral karyotyping. *Clin Genet* 2001;59:65-73.
7. Kakazu N, Ashihara E, Hada S, Ueda T, Sasaki H, Terada M, et al. Development of spectral colour banding in cytogenetic analysis. *Lancet* 2001; 357(9255):529-30.

Correspondence to: Dr. Alison Sinclair, 406-337 St. James St., Victoria BC V8V 1J7; fax 250 380-6717; alison Sinclair@shaw.ca

Association of Physicians of Canada, 1867 Alta Vista Dr., Ottawa ON K1G 3Y6; (Canada and US) cmamsc@cma.ca
800-263-2555; fax 613-233-8664

WANTED: INQUIRING MINDS

The CMAJ Editorial Fellowship: Come for a year, learn for a lifetime

Since *CMAJ* launched its 1-year Editorial Fellowship program in 1998, both sides have learned from the experience: editors have gained insights from doctors at the start of their careers, while the fellows have gained a behind-the-scenes look at how a medical journal is edited and produced. The program is aimed at recent graduates and residents, who will take a year away from their studies to work at *CMAJ*'s Ottawa office. The editorial fellow participates in all aspects of journal production, ranging from dealing with authors and helping to decide which manuscripts are published to soliciting commentaries. They are also expected to write extensively, and the first 4 fellows have taken lead roles in developing theme issues. Interested? We're considering applications for the next fellowship, which will begin July 1, 2003.

For information, contact Dr. John Hoey, Editor, at john.hoey@cma.ca; 800 663-7336 x2118; 1867 Alta Vista Dr., Ottawa ON K1G 3Y6. The deadline for applications is Dec. 16, 2002.

Applications are invited for the position of [redacted] Department of Obstetrics and Gynecology at [redacted] Hospital

"It provides a unique opportunity to sharpen research and writing skills and to establish relationships with physicians across the country. It lets you build a platform for issues and perspectives pertinent to new physicians and physicians in training."

— Dr. Erica Weir, 1999 Fellow

"The year really developed my skills as an editor and allowed me to get valuable writing experience. I loved witnessing first-hand new and interesting developments in medicine and health care."

— Dr. Eric Wooltorton, 2001 Fellow

CMAJ·JAMC